Vir Biotechnology, Inc. Form 8-K (May 5, 2022)

Summary

Form 8-K for an event dated May 5, 2022, filed by Vir Biotechnology, Inc. Under Item 2.02, Results of Operations and Financial Condition, the report states that on May 5, 2022, the company issued a press release announcing its financial results for the quarter ended March 31, 2022, attached as Exhibit 99.1. The report states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Howard Horn, Executive Vice President, Chief Financial Officer and Secretary, signed with the date May 5, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 05, 2022

Vir Biotechnology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware | 001-39083 | 81-2730369
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)
499 Illinois Street, Suite 500
San Francisco , California | 94158
(Address of Principal Executive Offices) | (Zip Code)
Registrant’s Telephone Number, Including Area Code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value | VIR | NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 5, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No. | Description
99.1 | Press Release of the Company, dated May 5, 2022
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIR BIOTECHNOLOGY, INC.
Date: | May 5, 2022 | By: | /s/ Howard Horn
Howard Horn Executive Vice President, Chief Financial Officer and Secretary

File and source

File

SEC_VIR_8-K_filed2022-05-05_0000950170-22-007820.htm

Size

53,979 bytes

SHA-256

95542e27c9be6525ddc182a0109ecf5f83cf7e843c08663a7cd4434cef92f644

Our copy

SEC_VIR_8-K_filed2022-05-05_0000950170-22-007820.htm

Original

www.sec.gov